Table 1 Main types of cancer treated with MR-Linac
From: Clinical application of MR-Linac in tumor radiotherapy: a systematic review
Tumor sites | Author | Time period | Reference | Treatment | No. of patients | Median follow-up (months) | Overall survival | Toxicity rates (≥ 3) (%) |
|---|---|---|---|---|---|---|---|---|
Nasopharyngeal carcinoma | Fu S et al | 4/2018–1/2020 | [25] | 70.4 Gy/32F | 130 | 25 | 100% (2 years) | 1.5 |
Lung tumor | Finazzi T et al | 2016–2018 | [41] | 60 Gy/8F (n = 28), 55 Gy/5F (n = 23), 54 Gy/3F (n = 2), 60 Gy/12F (n = 1) | 54 | 21.7 | 88.0% (1 years) | 8 |
Breast cancer | Nachbar M et al | 1/2019 | [50] | 40.05 Gy/15F | 1 | 3 | – | 0 |
Pancreatic cancer | Chuong MD et al | 2018–2021 | [62] | 50 Gy/5F | 62 | 18.6 | 40% (2 years) | 4.8 |
Cholangiocarcinoma | Luterstein E et al | 5/2015–8/2017 | [69] | 40 Gy/5F | 17 | 15.8 | 46.1% (2 years) | 5.9 |
Prostatic cancer | Bruynzeel AME et al | 10/2019–1/2020 | [78] | 35 Gy/5F | 25 | – | – | 0 |